Explore recent updates on skilled nursing care value, Medicare Advantage regulatory reforms, Medicaid hearing aid coverage expansion, and Alzheimer's treatment benefits impacting U.S. insurance and long-term care markets.
Explore recent US developments on federal drug price negotiation expansion to commercial plans, DEA telehealth prescribing extensions, the 340B rebate pilot launch, and ACA subsidy debates in the Senate impacting insurance and healthcare markets.
CMS announces a 9.7% increase in Medicare Part B premiums for 2026, affecting individuals earning $109,000 or less. Updates on oncology drug reimbursement and legal challenges to the CMS 340B drug rebate pilot program highlight shifting dynamics in Medicare regulation and healthcare compliance.
CMS has proposed key 2027 updates to Medicare Advantage and Part D Star Ratings aiming to streamline quality measures and modernize enrollment options to enhance care and plan accountability.
CMS announces $12 billion savings from Medicare drug price negotiations on 15 high-cost medications, effective 2027, enhancing Medicare Part D sustainability.
CMS's 2027 proposed rule outlines key Medicare Advantage and Part D program updates, codifying Inflation Reduction Act changes, adjusting Star Ratings, and modernizing marketing and risk adjustment frameworks.
OIG report identifies Medicare overpayments for continuous glucose monitors and urges CMS to reduce payment rates, highlighting potential savings.
Explore Georgia's key 2026 legislative changes impacting insurance affordability, state income tax reductions, consumer protections, teledentistry, property regulations, and more.
CMS releases 2027 Medicare Advantage and Part D proposed rule focusing on Star Ratings adjustments, regulatory burden reduction, and program spending projections.
CMS proposes significant updates to Medicare Advantage and Part D programs for 2027, including Star Ratings revisions and increased quality bonuses, impacting Medicare spending and compliance.
